A Placebo-controlled Trial of Daliresp on Chronic Obstructive Pulmonary Disease (COPD)
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to propose that roflumilast is associated with meaningful
reductions in biomarkers of pulmonary inflammation and sputum neutrophilia, including
confirmation of previously described results, and correlate these findings with improvement
in pulmonary function, sputum scores, and quality of life in stable moderate to severe COPD.
The investigators aim to demonstrate this regardless of concomitant medication use, including
inhaled corticosteroids. Additionally, the investigators hope to provide a mechanistic
pathway by which these effects occur.